Menu

Top Stories

Published on Wednesday, January 31, 2018

First John W. Walsh Translational Research Award granted

First John W. Walsh Translational Research Award granted

MIAMI/BOSTON, January 31, 2018 – The Alpha-1 Foundation celebrates the first granting of the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency, an honorable award named after John W. Walsh, co-founder of the Alpha-1 Foundation, a visionary man who dedicated his life’s work to finding a cure for Alpha-1 Antitrypsin Deficiency and helping those affected by Alpha-1.

The peer reviewing Committee received four very strong submissions, and the award was granted to Joseph Kaserman, MD, instructor of medicine at Boston University School of Medicine (BUSM) and a physician in Pulmonary, Allergy, Sleep and Critical Care Medicine at Boston Medical Center.

Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic (inherited) condition – it is passed from parents to their children through their genes. Alpha-1 may result in serious lung disease in adults and/or liver disease at any age.

The inaugural John W. Walsh Translational Research Award will be used by Kaserman to address a long outstanding question in the field of whether Alpha-1 carriers (these are individuals who have one normal Alpha1 gene (M) and one mutated gene (Z) have an increased risk of developing liver disease. As up to 2% of the U.S. population could be an Alpha-1 carrier there remains a critical need to address this important question.

For his research Kaserman will be working with specialized adult stem cells named induced pluripotent stem cells (iPSCs), which are stem cells that have been created from patients with Alpha-1 Antitrypsin Deficiency. Importantly, iPSCs contain all the genetic information of the original patient, and provide the ability to compare cells from patients that have the same mutation but different disease severity, i.e. patients who have the Z-mutation with or without liver damage.

To understand the risk associated with having either one or two Z genes, Kaserman will take advantage of a technology known as CRISPR that allows for altering or “editing” the DNA of cells including iPSCs that he has made from Alpha-1 patients. Using this approach, Kaserman will be able to conduct experiments comparing “ZZ”, “MZ”, and “MM” cells that all come from the same individual and thus are genetically identical, varying only at the site of the Alpha-1 Antitrypsin gene that has been edited.

Kaserman will then create liver cells from these iPSCs and examine whether MZ cells accumulate more misfolded AAT protein or are more susceptible to injury than MM cells. As there remain no approved therapies for Alpha-1 liver disease this study will also test new therapeutic agents targeting the mutated Z-protein within cells to see if this will protect the susceptible liver cells from injury.

Overall this study has the potential to not only address the concerns of many Alpha-1 carriers about their risk of developing liver disease, but also to find new treatments for Alpha-1 related liver disease helping both Alpha-1 carriers as well as Alpha-1 patients.

The award consists of up to a total of $225,000 ($75,000/year) over three years. The Alpha-1 Foundation, the Center for Regenerative Medicine of Boston University and Boston Medical Center, congratulate Kaserman, and look forward to the research findings, which will surely bring us closer to finding the cure for Alpha-1 Antitrypsin Deficiency (Alpha-1).

Back in October 2016, in recognition of John Walsh’s many contributions, Mark Brantly, MD, announced a $225,000 gift from himself and his wife Judy Lew, MD, to the Foundation during the Alpha-1 Donor Recognition Dinner. The gift was intended to be the first to establish the John W. Walsh Translational Research Award.

Brantly, professor of medicine, chief of molecular genetics and microbiology and Alpha-1 Foundation research professor at the University of Florida, said about John Walsh that “Judy and I believe that the best way to honor and thank him is to help carry on his commitment to a cure through this research award.”

“This is a tangible, concrete way to honor John and continue the work he was so committed to do,” said Henry Moehring, President and CEO of the Alpha-1 Foundation. “The Alpha-1 Foundation is honored that AlphaNet was able to make a matching contribution to this grant, enhancing even further the value we give to John’s legacy and his commitment to research”, added Moehring.

John Walsh’s leadership and passion helped shape the Alpha-1 Foundation into a successful organization and he was responsible for many of the Foundation’s accomplishments over more than two decades.

“This award, aimed specifically at translating research findings into medical practice, is intended to carry on Walsh’s commitment to find a cure for Alpha-1 Antitrypsin Deficiency”, expressed Moehring.

“We are extremely gratified that Kaserman has received this award, both because it is a huge honor to be selected to help carry out John’s vision and because of the significance this kind of award has in sustaining the career of a young researcher,” said Andrew Wilson, MD, Associate Professor of Medicine at BUSM, and Director of The Alpha-1 Center at Boston University and Boston Medical Center.

“John Walsh had a major impact on my career and on the Alpha-1 research that we carry out at the Center for Regenerative Medicine of Boston University and Boston Medical Center. John spoke openly about hopes for a cure for AATD and encouraged us to pursue major rather than incremental advances in our research efforts. He served as a mentor both to me and to Dr. Kotton and was instrumental in bringing us into the Alpha-1 community,” added Wilson.

“I am both excited and extremely humbled to have been selected as the inaugural recipient for the John W. Walsh Translational Research Award. Although I never had the pleasure of meeting John personally, I have heard numerous anecdotes from my mentor Dr. Wilson about how committed John was to the Foundation and how relentless he was about finding a cure for Alpha-1. As a pulmonologist caring for patients suffering from the complications of Alpha-1, I am continually reminded that our current therapies remain grossly inadequate, but this only reinforces the clinical relevance of our research especially if we are going to one day realize John’s goal of finding a cure for Alpha-1,” said Kaserman.

Boston Medical Center and the Boston University Pulmonary Center have long-standing ties to the Alpha-1 community through Gordon Snider, MD, the first chief of pulmonary medicine at Boston University, and a seminal clinician, teacher and researcher in the field. Snider’s work demonstrating the role of neutrophil elastase in the pathogenesis of emphysema, and interest in the role of Alpha-1 Antitrypsin (AAT) in protecting the lung against it, created a legacy that lives on today in the form of the research that Kaserman and Wilson carry out in their lab, as well as in the Alpha-1 Center, where they see patients with AATD.

###

About the Alpha-1 Foundation: The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. The Alpha-1 Foundation is a not-for-profit Florida corporation founded in 1995 by John Walsh, Sandy Lindsey and Susan Stanley, three people diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1). The Alpha-1 Foundation has invested more than $71 million to support Alpha-1 research and programs at 112 institutions in North America, Europe, the Middle East and Australia. For more information, visit www.alpha1.org. 

About the Center for Regenerative Medicine (CReM): The Center for Regenerative Medicine (CReM) is a collaborative effort among scientists at Boston University and the Boston Medical Center that aims to advance stem cell research and regenerative medicine for the sake of patients. Drs. Kaserman and Wilson’s lab is in the CReM, a state-of-the-art, multidisciplinary stem cell research facility that is home to 7 “primary investigators” (PIs) and their respective trainees. Dr. Kotton is CReM director and Wilson is one of the CReM PIs. Since its founding in 2013, AATD has been a major focus of research at the CReM, which houses the world’s largest repository of iPSCs created from patients with AATD. In keeping with a dedication to the philosophy of “Open-Source Biology”, CReM iPSCs are shared free of charge with researchers around the world to advance AATD research. Wilson, Kaserman, and Kotton provide clinical care to AATD patients and families at the Alpha-1 Center. The Alpha-1 Center features clinicians from multiple specialties, all experienced in caring for Alphas, to address all aspects of AATD. For more information about the CReM and the Alpha-1 Center, visit www.bumc.bu.edu/stemcells and www.alpha-1center.org.

Translational research in the biomedical field is understood as the application of basic knowledge acquired in the research laboratory to clinical practice, to improve medical care. This type of research is a necessary element for the success of any strategy that aims to improve the health of citizens through specific programs.

Press Release: PR Newswire


Print

Alpha-1 Foundation honors co-founder John W. Walsh with title of Director Emeritus

Wednesday, February 15, 2017
Alpha-1 Foundation Co-founder and visionary John W. Walsh has been named a Director Emeritus of the Board of Directors at the February 3, 2017 Board meeting. John W. Walsh “We have now passed the one-year anniversary of the accident...
Divider

Scientists battle in court over lucrative patents for gene-editing technology

Tuesday, December 6, 2016
The high-stakes fight over who invented a technology that could revolutionize medicine and agriculture heads to a courtroom Tuesday. Emmanuelle Charpentier (left) and Jennifer Doudna A gene-editing technology called CRISPR-cas9 could be...
Divider

Congress passes 21st Century Cures Act, boosting research and easing drug approvals

Monday, December 5, 2016
Congress passed sweeping legislation Wednesday that boosts funding for medical research, eases the development and approval of experimental treatments, and reforms federal policy on mental health care. The 94 to 5 Senate vote Wednesday followed...
Divider

RAPID trial extension study finds augmentation therapy slows disease progression, supports early intervention

Friday, December 2, 2016
The medical journal The Lancet Respiratory Medicine on Thursday, Dec. 1, published findings of the RAPID Open Label Extension study of augmentation therapy for patients with emphysema and Alpha-1 Antitrypsin Deficiency. N. Gerard...
Divider

House overwhelmingly passes 21st Century Cures bill

Thursday, December 1, 2016
WASHINGTON — The House overwhelmingly passed a far-reaching measure on Wednesday to increase funding for research into cancer and other diseases, address weaknesses in the nation’s mental health systems and help combat the prescription...
Divider

Arrowhead halts clinical trial of Alpha-1 liver drug candidate, plans to move ahead with subcutaneous AAT program

Wednesday, November 30, 2016
Arrowhead Pharmaceuticals has halted clinical trials of several potential drug therapies using its EX1 delivery system, including ARC-AAT, which had been showing good results in clinical trials to treat Alpha-1 liver disease, the company said in a...
Divider

Investigational drug showed deep reduction of alpha-1 protein in healthy volunteers, Arrowhead reports at Liver Meeting

Monday, November 14, 2016
Arrowhead Pharmaceuticals, Inc. delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver disease associated with Alpha-1...
Divider

FDA, Alpha-1 Foundation discuss placebos, trial of augmentation after lung transplants

Friday, September 30, 2016
Just over one year ago, members of the Alpha-1 community traveled from around the country to Silver Spring, Maryland for a meeting with the U.S. Food and Drug Administration (FDA).   Charlotte Mattison, right, gives emotional testimony...
Divider

PPTA statement says plasma protein products are safe, not affected by Zika virus

Saturday, September 24, 2016
The Plasma Protein Therapeutics Association (PPTA) has issued a statement saying that the safety of plasma protein therapies is not affected by the Zika virus (ZIKV). "According to recommendations from health authorities, measures such as...
Divider

Arrowhead begins Phase 2 trial of possible Alpha-1 liver treatment

Tuesday, September 6, 2016
California-based Arrowhead Pharmaceuticals Inc. announced Tuesday that it has begun a Phase 2 clinical study of ARC-AAT, the company's potential treatment for liver disease in people with Alpha-1 Antitrypsin Deficiency (AATD), using the...
Divider

Kamada Phase 2 trial shows promising results for inhaled augmentation

Wednesday, August 31, 2016
Kamada has released the results of a clinical trial showing that inhaled augmentation produces higher levels of alpha-1 protein in the airways than traditional intravenous augmentation. Mark Brantly, MD The company says the study’s...
Divider

ATS editorial warns against unregulated stem cell “treatments”

Monday, August 22, 2016
The Annals of the ATS, a publication of the American Thoracic Society, has published an editorial that warns against the use of unregulated, expensive stem cell remedies to treat severe respiratory diseases. The editorial, written by Laertis...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.